Related Experiment Videos
Protease inhibitors in chronic obstructive pulmonary disease
The American Review of Respiratory Disease
|May 1, 1975
Summary
Individuals with the alpha1-antitrypsin Pi MZ phenotype have an increased risk of developing chronic obstructive pulmonary disease (COPD). Lower inter-alpha-trypsin inhibitor levels were also observed in COPD patients.
Area of Science:
- Pulmonary Medicine
- Genetics
- Biochemistry
Background:
- Chronic obstructive pulmonary disease (COPD) is a major health concern.
- Plasma protease inhibitors play a role in lung health.
- Alpha1-antitrypsin is a key antiprotease in the lungs.
Purpose of the Study:
- To investigate the association between alpha1-antitrypsin phenotypes and COPD.
- To quantify major plasma protease inhibitors in COPD patients.
- To explore the role of other antiproteases in COPD pathogenesis.
Main Methods:
- Genetic typing of alpha1-antitrypsin (phenotype Pi).
- Quantification of plasma protease inhibitors.
- Comparison between 107 COPD patients and 91 healthy controls.
Main Results:
- Significantly higher frequency of PiZ gene and Pi MZ phenotype in COPD patients.
- Lower mean concentration of inter-alpha-trypsin inhibitor in COPD patients.
- No primary deficiency of other antiproteases found, but some had alpha1-antichymotrypsin deficiency.
Conclusions:
- The alpha1-antitrypsin Pi MZ phenotype is associated with an increased risk of COPD.
- Low serum concentrations of inter-alpha-trypsin inhibitor may be linked to COPD.
- Further research is needed to understand antiprotease roles in COPD.